Quantum Health Makes Eighth Appearance on the Inc. 5000 Fastest-Growing Companies List

Columbus, OH Aug 31, 2015 – Quantum Health, the leader in care coordination and consumer navigation, was once again recognized by Inc. magazine on the prestigious Inc. 5000 list, an annual ranking of the 5,000 fastest-growing privately held companies. Ranked 2,983 on the list, this is the seventh consecutive year Quantum Health has made the Inc. 5000. The company has been named to the list eight times since 2007, one of only ten health companies, and the only care coordination and consumer navigation company, to earn this distinction.
“We are extremely proud to again earn recognition as one of America’s fastest growing companies,” said Kara Trott, founder and chief executive officer, Quantum Health. “Our remarkable growth is a direct result of our ability to provide a superior personalized guided experience for healthcare consumers as well as help support our company’s mission of removing excess cost and confusion from the healthcare system.”
Quantum Health grew by 117% between 2011 and 2014, the timeframe used by Inc. for its annual ranking.
Quantum Health was the first to define and use consumer behavior process mapping in healthcare by tracking 3,200 patients and 290 providers for two years. From this research, the company built a best-in-class model for care coordination and navigation based on how people experience their healthcare journey, what they need and how best to connect with them.
Over the past 16 years, the company has earned recognition for its ability to deliver dramatic and sustainable results for large self-funded employers. Quantum Health clients experience nearly flat year one healthcare spend and a reduction in trend by year three as well as 92% member satisfaction by providing true patient support and advocacy for employees.
To qualify for the Inc. 5000, companies must have generated revenues of at least $100,000 in 2011 and at least $2 million in 2014. They must also be for-profit, independent and privately owned companies based in the United States. To view the ranking, visit http://www.inc.com/inc5000/list/2015/.

Cryotherapy Effective Treatment for Prostate Cancer – Star Beacon (Ashtabula County, OH)

Indianapolis, IN Aug 28, 2015 – HealthTronics’ Endocare® cryotherapy technology for prostate cancer was featured in Ashtabula County Star Beacon. A local Urologist and his patient discuss cryotherapy and how the freezing technology provides a potential alternative to surgery and radiation. You can read the entire article by clicking below.
http://www.starbeacon.com/community/cryotherapy-effective-treatment-for-prostate-cancer/article_8c9c8b7b-3010-51e9-b934-16912c978ba2.html

Altaris Capital Partners, LLC is pleased to announce an investment in Trean Corporation.

New York, NY Aug 19, 2015 – Altaris Capital Partners, LLC is pleased to announce an investment in Trean Corporation.
Trean is an insurance services company providing program management, reinsurance brokerage, consulting and risk transfer services to small and medium-sized insurance organizations. Trean also offers insurance underwriting services through its affiliate, Benchmark Insurance Company, an “A-” A.M. Best rated carrier which is licensed in 49 states.
Altaris is partnering with the company’s existing management team, led by Trean’s founder and President, Andy O’Brien.

Quantum Health Appoints Dana Andrews, M.D., MHSA as Chief Medical Officer

Columbus, OH Aug 18, 2015 – Quantum Health, the leader in care coordination and consumer navigation, announced today that it has named Dana Andrews, M.D., MHSA as chief medical officer effective immediately. Dr. Andrews will serve as leader of daily clinical operations and will be responsible for the oversight of case review and grand rounds cadence among other key clinical functions.
“Dana has been a part of Quantum Health since our founding and was part of our primary research team,” said Kara Trott, founder and chief executive officer of Quantum Health. “We are so pleased to have Dana join our executive team and take the reins of the clinical leadership for our daily operations, as well as help support our clinical strategy and overall mission of removing excess cost and confusion from the healthcare system.”
As a physician, Dr. Andrews has a private practice of approximately 2,500 patients in Mansfield, Ohio, and he is a managing partner of the Ohio division of the American Health Network, the largest multi-site primary care organization in Ohio with over 70 physician offices and more than 200 primary care physicians and specialists in Ohio and Indiana. Andrews received his B.A. from Capital University, his M.D. from The Ohio State University, and also holds a Masters in Health Service Administration from the University of Michigan. Dr. Andrews is also board certified in Internal Medicine and is a member of the American Academy of Sleep Medicine.
As part of the company’s founding research team, Dr. Andrews has spent over 15 years committed to the Quantum Health mission of providing a personalized, guided experience for clients and their health plan members. Quantum Health was the first to define and use consumer behavior process mapping in healthcare by tracking 3,200 patients and 290 providers for two years. From this research, the company built a best-in-class model for care coordination and consumer navigation based on how people experience their healthcare journey, what they need and how best to connect with them.

Altaris Capital Partners, LLC is pleased to announce that Precyse has been sold to funds managed by Pamplona Capital Management.

New York, NY Aug 11, 2015 – Altaris Capital Partners, LLC is pleased to announce that Precyse has been sold to funds managed by Pamplona Capital Management.
Precyse is a market leading provider of health information management (HIM) solutions. Altaris acquired Precyse in 2008 and, during its investment period, supported the company as it transformed from a transcription and coding service provider into a technology-driven clinical documentation and education partner for healthcare systems throughout the United States.
Precyse and Altaris Capital Partners were advised on this transaction by William Blair & Company, LLC and Kirkland & Ellis LLP.

Vascular Flow Technologies collaborates with SVS PSO and M2S® for a new post-market observational registry

Chicago, IL and West Lebanon, NH Jun 24, 2015 – The Society for Vascular Surgery® Patient Safety Organization and M2S, a leader in clinical registry development, today announced a new observational registry collaboration with Vascular Flow Technologies Ltd (UK). The SVS PSO Spiral Flow Technology AV Access Registry (STAAR) will be developed within the Vascular Quality Initiative® (VQI) using the M2S PATHWAYS clinical platform.
The SVS PSO evaluation of Vascular Flow Technology’s Spiral Laminar Flow™ Arteriovenous Graft will objectively measure the long-term safety, efficacy and cost effectiveness when used as the primary access for patients with end stage renal disease (ESRD) requiring routine hemodialysis. The STAAR project will recruit up to 15 participating centers in the US and enroll up to 75 patients with ESRD who require synthetic graft placement for hemodialysis access. Patients will be followed for a period of up to 12 months following graft implantation. The STAAR post market registry will collect intraoperative and acute post-operative outcomes in addition to long term graft performance in real world clinical practice as patients undergo routine dialysis. Experienced Data and Project Management teams from M2S have been chosen by the SVS PSO to support this project. An SVS PSO appointed Steering Committee, chaired by Richard Neville, M.D., will oversee the project, analysis, and publication of results. Sites will be selected to participate in this quality improvement project based on their volume of Hemodialysis Access procedures and interest in collecting additional procedure and follow-up data. Participating sites will be reimbursed for the expense of entering additional data for this project which allows sites to offset the cost of
participating in VQI.
Greg Lange, President and CEO of M2S, adds, “By leveraging the Vascular Quality Initiative platform, M2S’ experience managing clinical projects and the SVSPSO’s clinical oversight, VFT can observe real world performance of their Spiral Flow Graft in an efficient and unbiased manner. M2S is eager to support VFT in this effort and advance our mission to improve healthcare quality.”
Dr. Barbara Bunger, Chief Clinical Officer for Vascular Flow Technologies, commented: “We anticipate the STAAR dataset to help confirm existing studies showing Spiral Flow™ grafts have higher patency rates, and require fewer interventions than PTFE grafts resulting in lower costs to healthcare payers and healthcare providers.”